Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial.

Plain-language guide to PMID 25764996 (2015): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 47 children.

Key Facts

PMID: 25764996
Journal: Hormone research in paediatrics
Year: 2015
Study type: Randomized Controlled Trial
Authors: Bakker NE et al. (4 authors)
DOI: 10.1159/000374113

What This Study Did, in Plain Language

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Dietary management is a difficult but key aspect of care in children with Prader-Willi syndrome (PWS).

The researchers therefore investigated the effect of growth hormone (GH) treatment on reported energy intake in children with PWS, in relation with body composition, resting energy expenditure (REE) and hormone levels.

Who Took Part

According to the abstract, 47 children were involved.

The age groups tagged for this paper are infants, young children and children, both men and women.

In a randomized controlled GH trial including 47 children with PWS, the researchers assessed 5-day dietary records and dual-energy X-ray absorptiometry for body composition.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

REE was calculated by Müller's equation, based on fat mass, fat free mass and gender.

What Was Measured

Topics PubMed links to this paper include Body Composition, Diet, Energy Intake, Energy Metabolism, Human Growth Hormone, Motor Activity and Prader-Willi Syndrome.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 47 children.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (Hormone research in paediatrics), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.